APGE
Apogee Therapeutics, Inc.Healthcare · $8.4B market cap
Verdict
We can't put a fair value on APGE right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow APGE
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 2, 2026: no open-market purchases and 43 other filings (stock awards, tax withholding and similar). Why purchases matter
Other filings
Shah Nimish P
director · 2026-09-03
D-Return
365,853 shares
Shah Nimish P
director · 2026-09-03
D-Return
$651K
Shah Nimish P
director · 2026-09-03
D-Return
$602K
Shah Nimish P
director · 2026-09-03
D-Return
$455K
Shah Nimish P
director · 2026-09-03
D-Return
$812K
Show all 43 other filingsShow fewer
Shah Nimish P
director · 2026-09-03
D-Return
6,743,321 shares
Shah Nimish P
director · 2026-09-03
D-Return
$236.4M
HENDERSON MICHAEL THOMAS
Chief Executive Officer · 2026-09-03
D-Return
$19.2M
HENDERSON MICHAEL THOMAS
Chief Executive Officer · 2026-09-03
D-Return
$17.5M
HENDERSON MICHAEL THOMAS
Chief Executive Officer · 2026-09-03
D-Return
$8.8M
HENDERSON MICHAEL THOMAS
Chief Executive Officer · 2026-09-03
D-Return
920,941 shares
Bollinger Lisa
director · 2026-09-03
D-Return
$651K
Bollinger Lisa
director · 2026-09-03
D-Return
$602K
Bollinger Lisa
director · 2026-09-03
D-Return
$356K
Bollinger Lisa
director · 2026-09-03
D-Return
$888K
Henderson Jane
Chief Financial Officer · 2026-09-03
D-Return
$6.3M
Henderson Jane
Chief Financial Officer · 2026-09-03
D-Return
$6.1M
Henderson Jane
Chief Financial Officer · 2026-09-03
D-Return
$4.0M
Henderson Jane
Chief Financial Officer · 2026-09-03
D-Return
158,371 shares
Fox Jennifer A.
director · 2026-09-03
D-Return
$651K
Fox Jennifer A.
director · 2026-09-03
D-Return
$602K
Fox Jennifer A.
director · 2026-09-03
D-Return
$455K
Fox Jennifer A.
director · 2026-09-03
D-Return
34,824 shares
Dambkowski Carl
Chief Medical Officer · 2026-09-03
D-Return
$6.3M
Dambkowski Carl
Chief Medical Officer · 2026-09-03
D-Return
$6.1M
Dambkowski Carl
Chief Medical Officer · 2026-09-03
D-Return
$2.5M
Dambkowski Carl
Chief Medical Officer · 2026-09-03
D-Return
167,123 shares
JONES WILLIAM A JR
director · 2026-09-03
D-Return
$651K
JONES WILLIAM A JR
director · 2026-09-03
D-Return
$602K
JONES WILLIAM A JR
director · 2026-09-03
D-Return
$455K
JONES WILLIAM A JR
director · 2026-09-03
D-Return
34,824 shares
McKenna Mark C.
director · 2026-09-03
D-Return
$651K
McKenna Mark C.
director · 2026-09-03
D-Return
$602K
McKenna Mark C.
director · 2026-09-03
D-Return
$455K
McKenna Mark C.
director · 2026-09-03
D-Return
$3.5M
McKenna Mark C.
director · 2026-09-03
D-Return
20,000 shares
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
$651K
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
$602K
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
$455K
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
$812K
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
6,743,321 shares
Fairmount Funds Management LLC
director · 2026-09-03
D-Return
$6.9M
Dambkowski Carl
Chief Medical Officer · 2026-09-02
D-Return
$186K
About Apogee Therapeutics, Inc.
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Sep 4, 2026. How the Payback Price works